When epigenetics kills: MLL fusion proteins in leukemia

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Chromosomal aberrations at the 11q23 locus involving the Mixed Lineage Leukemia (MLL) gene are hallmarks of aggressive leukemia subtypes.
• These genetic alterations result in the formation of MLL fusion proteins, which possess potent transforming capabilities.
• Understanding the role of MLL in both normal development and malignant transformation is crucial for leukemia research.

Purpose of the Study:

• To review recent advancements in the understanding of normal and malignant MLL proteins.
• To highlight the epigenetic mechanisms influenced by MLL fusion proteins.
• To provide insights into the molecular basis of MLL-associated leukemias.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of studies focusing on MLL gene, its aberrations, and fusion proteins.
• Examination of research on epigenetic regulation in the context of MLL.

Main Results:

• MLL fusion proteins are key drivers in the pathogenesis of aggressive leukemias.
• These aberrant proteins significantly disrupt normal epigenetic processes.
• Recent studies have elucidated novel functions and regulatory pathways involving MLL.

Conclusions:

• MLL fusion proteins represent critical therapeutic targets in leukemia.
• Further research into MLL-mediated epigenetic dysregulation may uncover new treatment strategies.
• Advances in understanding MLL biology are paving the way for improved leukemia therapies.